M&A Deal Summary

Aditxt Acquires Appili Therapeutics

On April 2, 2024, Aditxt acquired life science company Appili Therapeutics

Acquisition Highlights
  • This is Aditxt’s 4th transaction in the Life Science sector.
  • This is Aditxt’s 1st transaction in Canada.
  • This is Aditxt’s 1st transaction in Nova Scotia.

M&A Deal Summary
Date 2024-04-02
Target Appili Therapeutics
Sector Life Science
Buyer(s) Aditxt
Deal Type Add-on Acquisition
Advisor(s) Dentons (Legal)

Target

Appili Therapeutics

Halifax, Nova Scotia, Canada
Appili Therapeutics is a biopharmaceutical company focused on anti-infective drug development. Appili provides drug development programs for unmet patient needs across a broad spectrum of infectious diseases. Appili Therapeutics was founded in 2015 and is based in Halifax, Canada.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aditxt

Richmond, Virginia, United States
Category Company
Founded 2017
Sector Life Science
Employees47
Revenue 1M USD (2023)
DESCRIPTION

Aditxt is developing technologies focused on improving the immune system's health through immune monitoring and reprogramming. Aditxt was founded in 2017 and is based in Richmond, Virginia.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 3 of 3
State (Nova Scotia) 1 of 1
Country (Canada) 1 of 1
Year (2024) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-01-30 Brain Scientific - portfolio of EEG brain monitoring technologies and devices

United States

Brain Scientific's portfolio of EEG brain monitoring technologies and devices includes 16 patents, with the flagship products being a disposable NeuroCap and portable NeuroEEG, intended to enable neurologists to streamline their processes by enhancing throughput, increasing patient comfort, and mitigating contamination risks.

Buy -
Mergr

Product

Company

Legal